Cytosorbents Corp (CTSO): Nasdaq/NYSE listing notice — CytoSorbents (CTSO) receives Nasdaq deficiency notice for bid price below $1.00

Cytosorbents Corp

Received Nasdaq notice on Oct 2, 2025, for non-compliance with Minimum Bid Price Requirement.
Stock traded below $1.00 per share for 30 consecutive business days prior to notice.
Company has 180 calendar days, until March 31, 2026, to regain compliance.
To cure, closing bid price must be at least $1.00 for 10 consecutive business days.
If not cured by deadline, may qualify for another 180-day period with a compliance plan.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cytosorbents Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 2, 2025, CytoSorbents Corporation (the “Company”) received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the Company’s common stock had fallen below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The written notification has no immediate effect on the listing or trading of the Company’s common stock. In accordance with applicable Nasdaq rules, the Company has 180 calendar days following the date of the written

View on SEC.gov

Browse all listing & compliance notices →

Cytosorbents Corp filing history →

Source: SEC EDGAR

accession 0001104659-25-096675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.